Opinion|Videos|November 8, 2024
From Guidelines to Practice: Advancing Lupus Nephritis Treatment
Author(s)Amit Saxena, MD
Amit Saxena, MD, discusses how evidence-based guidelines from ACR and KDIGO have evolved to shape lupus nephritis treatment approaches, emphasizing their critical role in standardizing patient care and incorporating recent advances like new therapeutic options and refined diagnostic criteria.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In your view, why are guidelines for lupus nephritis important to patient care?
- What role do the American College of Rheumatology (ACR) and Kidney Disease Improving Global Outcomes (KDIGO) guidelines play in shaping treatment practices for lupus nephritis?
- What are some of the most significant recent changes in lupus nephritis guidelines?
- How has the treatment approach for lupus nephritis evolved in recent years alongside these guidelines?
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
Using Complement Inhibitors in GA Comes With Pros and Cons
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5